CholesteniX Competitors and Similar CompaniesClear all
CholesteniX's competitors and similar companies include ACADIA Pharmaceuticals, Shionogi, Suven Life Sciences and Supernus Pharmaceuticals.
 CholesteniX CholesteniX is a company specializing in cholesterol metabolites and oxysterols in neurodegeneration. |  ACADIA Pharmaceuticals ACADIA Pharmaceuticals (formerly Receptor Technologies) is a biopharmaceutical company developing medicines that address medical needs in related central nervous system (CNS) disorders. |  Shionogi Shionogi (塩野義製薬株式会社) is a pharmaceutical company developing treatments for infectious, pain, and chronic liver diseases. |  Suven Life Sciences Suven Life Sciences is a biopharmaceutical company specialized in NCE-based CRAMS. |  Supernus Pharmaceuticals Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system disorders. | |
Founding Date | Founding Date 2013 | Founding Date 1993 | Founding Date 1878 | Founding Date 1989 | Founding Date 2005 |
Type | Type Private | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Sketty, GB HQ | Locations San Diego, US HQ Princeton, US | Locations Osaka, JP HQ Beijing, CN Hong Kong, HK Amagasaki, JP Amagasaki, JP Kanegasaki, JP Misato, JP see more | Locations Hyderabad, IN HQ Dasaigudem, IN Hyderabad, IN Sangareddy, IN South Brunswick Township, US | Locations Rockville, US HQ |
Employees | Employees 5 | Employees 513 | Employees 4,955 | Employees 141 | Employees 6527% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 2.4 b | Valuation ($) 12.3 b | Valuation ($) N/A | Valuation ($) 1.9 b |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $1.1b (FY, 2025) | Revenue (est.) ¥499.7b (FY, 2026) | Revenue (est.) ₹71.1m (FY, 2026) | Revenue (est.) $719m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods $89m (FY, 2025) | Cost of goods ¥55.5b (FY, 2026) | Cost of goods N/A | Cost of goods $74.6m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit $982.5m (FY, 2025) | Gross profit ¥491.3b (FY, 2026) | Gross profit ₹210.4m (FY, 2026) | Gross profit $644.4m (FY, 2025) |
Net income | Net income N/A | Net income $391m (FY, 2025) | Net income ¥205.9b (FY, 2026) | Net income (₹2.8b) (FY, 2026) | Net income ($38.6m) (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 770.8m | Total funding raised $ 4.7m | Total funding raised $ 32m | Total funding raised $ 69.5m |
For sources of this data, please see the company profile
View Company Profiles
ACADIA Pharmaceuticals
HQ
San Diego, US
Employees
513
ACADIA Pharmaceuticals (formerly Receptor Technologies) is a biopharmaceutical company developing medicines that address medical needs in related central nervous system (CNS) disorders.
View companyShionogi
HQ
Osaka, JP
Employees
4,955
Shionogi (塩野義製薬株式会社) is a pharmaceutical company developing treatments for infectious, pain, and chronic liver diseases.
View companySuven Life Sciences
HQ
Hyderabad, IN
Employees
141
Suven Life Sciences is a biopharmaceutical company specialized in NCE-based CRAMS.
View companySupernus Pharmaceuticals
HQ
Rockville, US
Employees
652↑ 7% increase
Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system disorders.
View company